You just read:

New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort

News provided by

Ivantis, Inc.

Apr 12, 2018, 09:05 ET